| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1091237216 |
| P356 | DOI | 10.1007/S00401-017-1769-8 |
| P698 | PubMed publication ID | 28821944 |
| P2093 | author name string | M Beatriz S Lopes | |
| P2860 | cites work | Pituicytoma, spindle cell oncocytoma, and granular cell tumor: clarification and meta-analysis of the world literature since 1893 | Q28249369 |
| Cushing's Disease and Hyperprolactinemia Due to a Mixed ACTH- and Prolactin-Secreting Pituitary Macroadenoma | Q28321729 | ||
| Mixed Gangliocytoma-Pituitary Adenoma: Insights on the Pathogenesis of a Rare Sellar Tumor | Q30275021 | ||
| Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study | Q30276702 | ||
| Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria | Q30307884 | ||
| Clinical Characteristics of Silent Corticotrophic Adenomas and Creation of an Internet-accessible Database to Facilitate Their Multi-institutional Study | Q30311929 | ||
| Pituitary carcinoma: diagnosis and treatment | Q30438799 | ||
| Spindle cell oncocytomas and granular cell tumors of the pituitary are variants of pituicytoma | Q30456831 | ||
| Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype | Q30458346 | ||
| Silent corticotroph adenomas after stereotactic radiosurgery: a case-control study | Q30459098 | ||
| Double, synchronous pituitary adenomas causing acromegaly and Cushing's disease. A case report and review of literature | Q30604166 | ||
| Computer-Assisted Microscope Analysis of Feulgen-Stained Nuclei in Gonadotroph Adenomas and Null-Cell Adenomas of the Pituitary Gland | Q30836323 | ||
| Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics | Q30870274 | ||
| Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modifications | Q30987978 | ||
| Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form | Q33352130 | ||
| Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations | Q34030921 | ||
| Pituitary development: regulatory codes in mammalian organogenesis | Q34120136 | ||
| Double pituitary lesions in three patients with Cushing's disease | Q34268112 | ||
| Pituitary carcinoma: a review of the literature | Q34548556 | ||
| Recurrent gain-of-function USP8 mutations in Cushing's disease | Q35146226 | ||
| Silent corticotroph adenomas | Q35224340 | ||
| The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease | Q35813265 | ||
| Transcriptional control of precursor proliferation in the early phases of pituitary development | Q35893546 | ||
| Silent adenoma subtype 3 of the pituitary--immunohistochemical and ultrastructural classification: a review of 29 cases. | Q36326541 | ||
| Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry | Q36730948 | ||
| Succinate dehydrogenase (SDHx) mutations in pituitary tumors: could this be a new role for mitochondrial complex II and/or Krebs cycle defects? | Q36865610 | ||
| Multiple adenomas of the human pituitary. A retrospective autopsy study with clinical implications | Q37626646 | ||
| Atypical pituitary adenomas: incidence, clinical characteristics, and implications | Q37792065 | ||
| Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. | Q37992191 | ||
| Primary sellar neuroblastoma. A new case and review of literature | Q38002146 | ||
| Plurihormonal pituitary adenoma with concomitant adrenocorticotropic hormone (ACTH) and growth hormone (GH) secretion: a report of two cases and review of the literature | Q38148057 | ||
| Aggressive pituitary adenomas--diagnosis and emerging treatments | Q38211375 | ||
| Aggressive pituitary tumors. | Q38311673 | ||
| 15 YEARS OF PARAGANGLIOMA: The association of pituitary adenomas and phaeochromocytomas or paragangliomas | Q38538317 | ||
| Genetic Aspects of Pituitary Adenomas | Q39286310 | ||
| Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience | Q39890682 | ||
| Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas | Q40131008 | ||
| Steroidogenic Factor 1, Pit-1, and Adrenocorticotropic Hormone: A Rational Starting Place for the Immunohistochemical Characterization of Pituitary Adenoma | Q40377390 | ||
| The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas | Q40415363 | ||
| Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. | Q41190054 | ||
| Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis. | Q41508895 | ||
| Transcription factors in normal and neoplastic pituitary tissues | Q41636025 | ||
| Mutations in the deubiquitinase gene USP8 cause Cushing's disease | Q41716700 | ||
| Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance | Q42480261 | ||
| Crooke's cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma | Q44595742 | ||
| GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. | Q46028427 | ||
| Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. | Q46043940 | ||
| A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas | Q46126491 | ||
| A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. | Q46411571 | ||
| Pituitary blastoma | Q46542122 | ||
| The adrenal medulla and extra-adrenal paraganglia: then and now. | Q48110909 | ||
| Double adenomas of the pituitary: a clinicopathological study of 11 tumors | Q48416535 | ||
| Thyroid transcription factor 1 expression in sellar tumors: a histogenetic marker? | Q48570682 | ||
| Pituitary blastoma: a unique embryonal tumor | Q48973734 | ||
| Germline and somatic DICER1 mutations in a pituitary blastoma causing infantile-onset Cushing's disease. | Q50471525 | ||
| Low rate of germline AIP mutations in patients with apparently sporadic pituitary adenomas before the age of 40: a single-centre adult cohort. | Q50636930 | ||
| Predictors of aggressive clinical phenotype among immunohistochemically confirmed atypical adenomas. | Q51372242 | ||
| Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. | Q53093914 | ||
| Cytokeratin CK 7 and CK 20 expression in pituitary adenomas. | Q53648314 | ||
| Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. | Q54523330 | ||
| Immunoreactive luteinizing hormone in functioning corticotroph adenomas of the pituitary | Q57795663 | ||
| P433 | issue | 4 | |
| P921 | main subject | World Health Organization | Q7817 |
| P304 | page(s) | 521-535 | |
| P577 | publication date | 2017-08-18 | |
| P1433 | published in | Acta Neuropathologica | Q343168 |
| P1476 | title | The 2017 World Health Organization classification of tumors of the pituitary gland: a summary | |
| P478 | volume | 134 |
| Q89731986 | A novel diagnostic method for pituitary adenoma based on magnetic resonance imaging using a convolutional neural network |
| Q88956907 | Advances and controversies in the classification and grading of pituitary tumors |
| Q90127998 | Aggressive Pituitary Tumor with Crooke's Cells and Invasion of the Posterior Fossa |
| Q99406272 | Analysis of whole genome-wide microRNA transcriptome profiling in invasive pituitary adenomas and non-invasive pituitary adenomas |
| Q64062715 | Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities |
| Q90016847 | Clinical Vasospasm After an Extended Endoscopic Endonasal Approach for Recurrent Pituitary Adenoma: Illustrative Case and Systematic Review of the Literature |
| Q89453226 | Clinical and Pathologic Characteristics Predicted the Postoperative Recurrence and Progression of Pituitary Adenoma: A Retrospective Study with 10 Years Follow-Up |
| Q89220451 | Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study |
| Q91799529 | Clinicopathologic Characteristics and Surgical Treatment of Plurihormonal Pituitary Adenomas |
| Q90480552 | Clinicopathological analysis of 250 cases of pituitary adenoma under the new WHO classification |
| Q64965645 | Co-expression Network Analysis Elucidated a Core Module in Association With Prognosis of Non-functioning Non-invasive Human Pituitary Adenoma. |
| Q90855144 | Combined Endoscopic Endonasal and Video-microscopic Transcranial Approach with Preoperative Embolization for a Posterior Pituitary Tumor |
| Q97419894 | Contemporary Management of Clinically Non-functioning Pituitary Adenomas: A Clinical Review |
| Q48100937 | Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review. |
| Q52572091 | Cystic tumors of the pituitary infundibulum: seminal autopsy specimens (1899 to 1904) that allowed clinical-pathological craniopharyngioma characterization. |
| Q97527500 | Decrease of Proliferative Potential and Vascular Density of Giant Prolactinoma in Patients Treated with Cabergoline |
| Q91545412 | Effect of Hormone Levels and Aging on Cognitive Function of Patients with Pituitary Adenomas Prior to Medical Treatment |
| Q104471890 | Endoscopic vs. microscopic transsphenoidal pituitary surgery: a single centre study |
| Q92909603 | Endothelial cell-specific molecule-1 as an invasiveness marker for pituitary null cell adenoma |
| Q47840801 | Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas |
| Q89565313 | Expression patterns of ERα66 and its novel variant isoform ERα36 in lactotroph pituitary adenomas and associations with clinicopathological characteristics |
| Q47185873 | Extent of surgical resection and tumor size predicts prognosis in granular cell tumor of the sellar region. |
| Q49357332 | Genomic Alterations in Sporadic Pituitary Tumors |
| Q89425199 | Headaches in Patients with Pituitary Tumors: a Clinical Conundrum |
| Q60907459 | High Expression of Somatostatin Receptors 2A, 3, and 5 in Corticotroph Pituitary Adenoma |
| Q47252651 | Histopathological classification of non-functioning pituitary neuroendocrine tumors |
| Q89880298 | How to Classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020 |
| Q64887455 | Immunohistochemical Study of NR2C2, BTG2, TBX19, and CDK2 Expression in 31 Paired Primary/Recurrent Nonfunctioning Pituitary Adenomas. |
| Q64096554 | Increased expression of NAF1 contributes to malignant phenotypes of glioma cells through promoting protein synthesis and associates with poor patient survival |
| Q59315841 | Intraoperative low field MRI in transsphenoidal pituitary surgery |
| Q89445122 | Is it time to consider the expression of specific-pituitary hormone genes when typifying pituitary tumours? |
| Q89604160 | Ki67 as a prognostic factor of craniopharyngioma's recurrence in paediatric population |
| Q95322639 | LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma |
| Q97646327 | Malignancy course of pituitary adenoma in MEN1 syndrome: Clinical-Neuroradiological signs |
| Q49330862 | Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma). |
| Q47726143 | Management of NFAs: medical treatment. |
| Q49670308 | Management of nonfunctioning pituitary tumors: radiotherapy |
| Q90656375 | Management of pituicytomas: a multicenter series of eight cases |
| Q61810261 | Molecular Network Basis of Invasive Pituitary Adenoma: A Review |
| Q92264924 | Molecular pathology of tumors of the central nervous system |
| Q95936527 | Nanomedicine-based immunotherapy for central nervous system disorders |
| Q47873034 | New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors |
| Q58724622 | Non-secreting pituitary tumours characterised by enhanced expression of YAP/TAZ |
| Q91107698 | Nonfunctioning Pituitary Adenoma Recurrence and Its Relationship with Sex, Size, and Hormonal Immunohistochemical Profile |
| Q64091861 | Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience |
| Q96303471 | Pituispheres Contain Genetic Variants Characteristic to Pituitary Adenoma Tumor Tissue |
| Q93258158 | Pituitary Blastoma in a 19-Year-Old Woman: A Case Report and Review of Literature |
| Q64064961 | Plurihormonal Pit-1 lineage adenoma presenting as meningitis with recurrence after somatostatin analogue |
| Q57054647 | Posterior pituitary tumours: the spectrum of a unique entity. A clinical and histological study of a large case series |
| Q89639948 | Predicting the likelihood of early recurrence based on mRNA sequencing of pituitary adenomas |
| Q99357619 | Primary tumors of the Posterior Pituitary gland: A systematic review of the literature in light of the new 2017 WHO classification of pituitary tumors |
| Q55379525 | Prolactin-Producing Pituitary Carcinoma, Hypopituitarism, and Graves' Disease-Report of a Challenging Case and Literature Review. |
| Q98177581 | Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery |
| Q92317505 | Rare Thyroid Transcription Factor 1-Positive Tumors of the Sellar Region: Barrow Neurological Institute Retrospective Case Series |
| Q52603286 | Recurrent non-functioning pituitary adenomas: a review on the new pathological classification, management guidelines and treatment options. |
| Q90705829 | Regulating the CCNB1 gene can affect cell proliferation and apoptosis in pituitary adenomas and activate epithelial-to-mesenchymal transition |
| Q92471631 | Sellar surprises: a single-centre experience of unusual sellar masses |
| Q47203293 | Silent somatotroph pituitary adenomas: an update |
| Q93367521 | Spindle cell oncocytoma of the pituitary gland |
| Q55370601 | Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions. |
| Q92071279 | The Apoptosis Regulator 14-3-3η and Its Potential as a Therapeutic Target in Pituitary Oncocytoma |
| Q64268853 | The Epigenomics of Pituitary Adenoma |
| Q91817572 | The Role of Single-Nucleotide Polymorphisms in Pituitary Adenomas Tumorigenesis |
| Q52572072 | The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy. |
| Q64994431 | The long non-coding RNA SNHG1 promotes glioma progression by competitively binding to miR-194 to regulate PHLDA1 expression. |
| Q57822729 | Updates in Diagnosis and Treatment of Acromegaly |
Search more.